Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inge Dierynck

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Virology Journal|June 3, 2014
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevirSandra De Meyer, Anne Ghys, Inge Dierynck, et al.
Journal of Virology|October 12, 2007
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrierInge Dierynck, Mieke De Wit, Emmanuel Gustin, et al.
Journal of Virology|June 29, 2007
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 proteaseMadhavi N L Nalam, Anik Peeters, Tim H M Jonckers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2013
Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studiesRichard M W Hoetelmans, Inge Dierynck, Ilham Smyej, et al.
Antiviral Therapy|February 12, 2011
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysisErkki Lathouwers, Sandra De Meyer, Inge Dierynck, et al.
The Journal of Infectious Diseases|June 20, 2014
Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE studyInge Dierynck, Kim Thys, Anne Ghys, et al.
Journal of Clinical Microbiology|February 6, 2015
An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assayChristoph Sarrazin, Inge Dierynck, Gavin Cloherty, et al.
Antiviral Therapy|December 15, 2010
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patientsInge Dierynck, Sandra De Meyer, Erkki Lathouwers, et al.
Archives of Biochemistry and Biophysics|May 16, 2012
A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional NanobodiesMireille Pellis, Els Pardon, Kourosh Zolghadr, et al.
AIDS (London, England)|September 3, 2009
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescentsStéphane Blanche, Rosa Bologna, Pedro Cahn, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Virology Journal|June 3, 2014
Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevirSandra De Meyer, Anne Ghys, Inge Dierynck, et al.
Journal of Virology|October 12, 2007
Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrierInge Dierynck, Mieke De Wit, Emmanuel Gustin, et al.
Journal of Virology|June 29, 2007
Crystal structure of lysine sulfonamide inhibitor reveals the displacement of the conserved flap water molecule in human immunodeficiency virus type 1 proteaseMadhavi N L Nalam, Anik Peeters, Tim H M Jonckers, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2013
Safety and pharmacokinetics of the HIV-1 protease inhibitor TMC310911 coadministered with ritonavir in healthy participants: results from 2 phase 1 studiesRichard M W Hoetelmans, Inge Dierynck, Ilham Smyej, et al.
Antiviral Therapy|February 12, 2011
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysisErkki Lathouwers, Sandra De Meyer, Inge Dierynck, et al.
The Journal of Infectious Diseases|June 20, 2014
Deep-sequencing analysis of the gene encoding the hepatitis C virus nonstructural 3-4A protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE studyInge Dierynck, Kim Thys, Anne Ghys, et al.
Journal of Clinical Microbiology|February 6, 2015
An OPTIMIZE study retrospective analysis for management of telaprevir-treated hepatitis C virus (HCV)-infected patients by use of the Abbott RealTime HCV RNA assayChristoph Sarrazin, Inge Dierynck, Gavin Cloherty, et al.
Antiviral Therapy|December 15, 2010
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patientsInge Dierynck, Sandra De Meyer, Erkki Lathouwers, et al.
Archives of Biochemistry and Biophysics|May 16, 2012
A bacterial-two-hybrid selection system for one-step isolation of intracellularly functional NanobodiesMireille Pellis, Els Pardon, Kourosh Zolghadr, et al.
AIDS (London, England)|September 3, 2009
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescentsStéphane Blanche, Rosa Bologna, Pedro Cahn, et al.
Pageof 3